drugset / Trial / NCT04743739

Summary

The primary objective of this study is to determine whether or not cyclosporine (CsA) combined with RTX is more effective than RTX alone in the treatment of idiopathic membranous nephropathy (iMN).

Timeline

Start
2021-04-14
Primary completion
2022-12-20
Completion
2024-12-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 3 mg/kg
Subject Rituximab Monoclonal antibody 1000 mg Intravenous